Webinar: Pharmacovigilance

TGA's Compliance Push

The Therapeutic Goods Administration (TGA), Australia's gatekeeper for medicines and medical devices, released its Compliance Principles for 2026 and 2027 in January 2026. This update refreshes the agency's approach after reviewing the 2023-2025 priorities, introducing a clearer framework for monitoring and enforcing rules across the entire supply chain.

At the core are five principles guiding action: protecting public health, empowering consumers with better information, proportionate responses to breaches, transparency in decision-making, and collaboration with stakeholders. These underpin a risk-based model that targets emerging threats more nimbly than before.

Pharmacovigilance sits squarely in the crosshairs. Sponsors must maintain watertight systems for detecting, assessing, and reporting safety issues—serious adverse reactions within 15 days, significant safety issues in 72 hours. Non-compliance can trigger inspections, product recalls, fines, or ARTG suspensions, directly hitting revenue and reputation.

Recent signals amplify the pressure. The TGA continues monthly Product Information safety updates, flagging new warnings for everything from antibiotics to vaccines. Meanwhile, the integration of AI tools in safety monitoring draws fresh guidance and scrutiny; companies using AI for signal detection or case processing must ensure compliance or risk classification as regulated devices.

Stakeholders face trade-offs. Budget-constrained firms struggle to scale PV operations amid rising data volumes, yet inaction invites regulatory heat. The TGA's focus on proactive enforcement—regular priority reviews and firm action on breaches—means companies cannot afford outdated processes.

The June 2026 timing aligns with a year where PV foundations like strong signal management, clear benefit-risk communication, clean documentation, and inspection readiness dominate industry discussions in Australia.